Clinical Observation of Gene Polymorphism of Olanzapine or Aprepitant in Prevention of CINV.
chemotherapy-induced nausea and vomiting
cisplatin
gene polymorphism
multi-day chemotherapy
Journal
Pharmacogenomics and personalized medicine
ISSN: 1178-7066
Titre abrégé: Pharmgenomics Pers Med
Pays: New Zealand
ID NLM: 101514107
Informations de publication
Date de publication:
2021
2021
Historique:
received:
23
04
2021
accepted:
22
06
2021
entrez:
22
7
2021
pubmed:
23
7
2021
medline:
23
7
2021
Statut:
epublish
Résumé
The present study aims to investigate the correlation between the gene polymorphisms of the multidrug resistance protein 1 (ABCB1), the intron region of transcriptional factor (GTF2E1) and catechol- Antiemetic treatment with 5 mg of olanzapine or aprepitant triplet therapy was conducted in 210 patients with malignancies receiving cisplatin multi-day chemotherapy. The general data on the patients were collected with the evaluation of the rate of complete protection (TP), complete remission (CR), complete control (TC), and time to first vomiting, the functional living index-emesis (FLIE) scale, and side effects in the acute and delayed phases. The DNA mass spectrometry detected the gene polymorphisms of ABCB1, GTF2E1, COMT, and DRD2, and the correlation with TP was analyzed. 1) There were no statistically significant differences in the TP, CR, TC, time of first vomiting, and FLIE index at different phases between the 5mg of olanzapine group and the aprepitant group (P > 0.05). 2) The main side effect in the olanzapine group was drowsiness (P = 0.00), and in the aprepitant group was constipation (P = 0.02). 3) The distributions of each genotype were in the Hardy-Weinberg (H-W) equilibrium. Univariate analysis showed that in the olanzapine group, delayed-phase TP was correlated with the ABCB1 rs1045642 non-TT (P = 0.01) genotype. The present study revealed that females and the rs1045642TT genotype were independent risk factors for delayed-phase CINV in the northern Chinese population, which provided a scientific basis for subsequent CINV-related analysis of high-risk factors in Chinese patients.
Identifiants
pubmed: 34290520
doi: 10.2147/PGPM.S317229
pii: 317229
pmc: PMC8289460
doi:
Types de publication
Journal Article
Langues
eng
Pagination
867-875Informations de copyright
© 2021 Jin et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Lancet Oncol. 2020 Feb;21(2):242-249
pubmed: 31838011
Basic Clin Pharmacol Toxicol. 2015 Apr;116(4):354-60
pubmed: 25286968
Front Pharmacol. 2020 Apr 01;11:329
pubmed: 32296333
J Support Oncol. 2011 Sep-Oct;9(5):188-95
pubmed: 22024310
Exp Brain Res. 2014 Aug;232(8):2613-25
pubmed: 24792505
Support Care Cancer. 2006 Apr;14(4):354-60
pubmed: 16450086
Pharmacogenomics. 2014;15(12):1565-74
pubmed: 25340731
Basic Clin Pharmacol Toxicol. 2018 Oct;123(4):474-485
pubmed: 29723928
Clin Ther. 2014 Aug 1;36(8):1242-1252.e2
pubmed: 25012726
Drug Metab Pharmacokinet. 2013;28(4):299-304
pubmed: 23358260
Int J Clin Pharm. 2011 Feb;33(1):33-43
pubmed: 21365391
Support Care Cancer. 2020 Nov;28(11):5335-5342
pubmed: 32128615
Br J Clin Pharmacol. 2005 Aug;60(2):159-71
pubmed: 16042669
Pharmacogenomics J. 2013 Jun;13(3):209-17
pubmed: 22310351
Eur J Cancer. 2011 Jul;47(11):1682-91
pubmed: 21570824
Clin Pharmacol Ther. 2002 Apr;71(4):297-303
pubmed: 11956513
Cancer Chemother Pharmacol. 2021 Jan;87(1):73-83
pubmed: 33099677
Pharmacogenomics J. 2017 Oct;17(5):435-440
pubmed: 27241063
Eur Psychiatry. 2007 Jul;22(5):276-81
pubmed: 17419009
J Clin Oncol. 2016 Feb 1;34(4):381-6
pubmed: 26527784
Open Med (Wars). 2018 Mar 15;13:29-34
pubmed: 29577093
Support Care Cancer. 2016 Feb;24(2):675-682
pubmed: 26130365
Clin Pharmacol Ther. 2005 Dec;78(6):619-26
pubmed: 16338277
Clin Pharmacol Ther. 2003 Jul;74(1):17-24
pubmed: 12844131
Biol Pharm Bull. 2016;39(11):1852-1858
pubmed: 27803457